The reiteration of an Overweight rating and a high price target of $120 by a reputable analyst like Charles Duncan from Cantor Fitzgerald could lead to increased investor confidence in Intra-Cellular Therapies. This positive endorsement is likely to have a favorable impact on the stock's short-term price movement, as it reaffirms the company's strong prospects.